Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$9 Mln
Revenue (TTM)
$25 Mln
Net Profit (TTM)
$-37 Mln
ROE
-13.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
-1.6
Div. Yield
0 %
Debt to Equity
-3.2
Book Value
$--
EPS
$-1.3
Face value
--
Shares outstanding
29,000,100
CFO
€-92.03 Mln
EBITDA
€-102.03 Mln
Net Profit
€-184.76 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Centogene N.V. - ADR
| -55.4 | -58.1 | -58.6 | -81.3 | -65.3 | -65.8 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Centogene N.V. - ADR
| 29.0 | -82.2 | -51.5 | 7.1 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Centogene N.V. - ADR
|
0.1 | 9.4 | 48.5 | -35.5 | -117.5 | 397.6 | -- | 0.9 |
| 0.1 | 3.0 | 0.9 | -70.0 | -7,823.0 | -241.9 | -- | 0.1 | |
| 4.7 | 1,049.3 | 510.5 | 193.6 | -21.7 | 25.5 | 7 | 1.0 | |
| 0.9 | 60.1 | 0.0 | -43.8 | -173,594.0 | -85.1 | -- | 1.4 | |
| 1.7 | 45.8 | 5.0 | -23.3 | -442.3 | -121 | -- | 3.6 | |
| 28.6 | 1,772.7 | 0.0 | -163.7 | -- | -60.9 | -- | 4.7 | |
| 1.7 | 159.1 | 15.3 | -40.5 | -271.2 | -58.8 | -- | 2.9 |
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and... pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany. Read more
CEO & Member of Management Board
Ms. Kim Stratton
CEO & Member of Management Board
Ms. Kim Stratton
Headquarters
Rostock
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Centogene NV - ADR is $0.06 (NASDAQ) as of 11-Aug-2025 09:30 EDT. Centogene NV - ADR has given a return of -65.25% in the last 3 years.
Since, TTM earnings of Centogene NV - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.94
|
-1.33
|
|
2022
|
--
|
--
|
|
2021
|
-2.65
|
4.49
|
|
2020
|
-10.02
|
3.30
|
|
2019
|
-9.59
|
3.34
|
The 52-week high and low of Centogene NV - ADR are Rs 0.35 and Rs 0.00 as of 03-Apr-2026.
Centogene NV - ADR has a market capitalisation of $ 9 Mln as on 11-Aug-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Centogene NV - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.